Opfolda Europese Unie - Letlands - EMA (European Medicines Agency)

opfolda

amicus therapeutics europe limited - miglustat - glikogēna uzglabāšanas slimības ii tipa - citi gremošanas trakta un vielmaiņas produkti - opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset pompe disease (acid α- glucosidase [gaa] deficiency).

Tyenne Europese Unie - Letlands - EMA (European Medicines Agency)

tyenne

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imūnsupresanti - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Sotyktu Europese Unie - Letlands - EMA (European Medicines Agency)

sotyktu

bristol-myers squibb pharma eeig - deucravacitinib - psoriāze - imūnsupresanti - treatment of moderate-to-severe plaque psoriasis in adults.

Mycophenolate mofetil Teva Europese Unie - Letlands - EMA (European Medicines Agency)

mycophenolate mofetil teva

teva pharma b.v. - mikofenolāta mofetils - transplanta noraidīšana - imūnsupresanti - mycophenolate mofetil teva norāda kopā ar ciklosporīni un kortikosteroīdi transplantācijas akūtas noraidījumu saņem homologu nieru, sirds un aknu pārstādīšana pacientiem profilakses.

Kexxtone Europese Unie - Letlands - EMA (European Medicines Agency)

kexxtone

elanco gmbh - monenzīns (monenzīna nātrija sāls) - narkotiku profilaksei un/vai ārstēšanai acetonemia - liellopi (govis un teļi) - lai samazinātu ketozes sastopamību peritropieliskajā piena govs / telē, no kuras sagaidāms ketoze.

Myclausen Europese Unie - Letlands - EMA (European Medicines Agency)

myclausen

passauer pharma gmbh - mikofenolāta mofetils - transplanta noraidīšana - imūnsupresanti - myclausen indicēts kombinācijā ar ciklosporīnu un kortikosteroīdiem akūtas transplantāta atgrūšanas profilaksei pacientiem, kuri saņem alogēnas nieru, sirds vai aknu transplantācijas.

Litfulo Europese Unie - Letlands - EMA (European Medicines Agency)

litfulo

pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - imūnsupresanti - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

Vitamin E + Selenium šķīdums injekcijām Letland - Letlands - Pārtikas un veterinārais dienests, Zemkopības ministrija

vitamin e + selenium šķīdums injekcijām

bremer pharma gmbh, vācija - vitamīna e acetāts,nātrija selenīta - šķīdums injekcijām - aitas; cūkas; kazas; kaķi; liellopi; suņi; zirgi

Terizidon Fatol 250 mg cietās kapsulas Letland - Letlands - Zāļu valsts aģentūra

terizidon fatol 250 mg cietās kapsulas

esteve pharmaceuticals gmbh, germany - terizidons - kapsula, cietā - 250 mg

PGF Veyx Letland - Letlands - Pārtikas un veterinārais dienests, Zemkopības ministrija

pgf veyx

veyx-pharma gmbh, vācija - nātrija cloprostenol - šķīdums injekcijām - 0.0875 mg/ml - cūkas; liellopi